Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom’s Macroglobulinemia
The MYD88 L265P somatic variant (MYD88) has a high prevalence in Waldenstrom’s Macroglobulinemia (WM), a form of lymphoplasmacytic lymphoma (LPL) associated with monoclonal IgM. Although the role of MYD88 in WM was initially reported in 2012, it was not until 2016 that MYD88 testing was included in...
Saved in:
Main Authors: | D. Kazmierski, M. L. Palomba, C. Barsigian |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2017/5183646 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
by: Maroun Bou Zerdan, et al.
Published: (2022-01-01) -
CNS Vasculitis Associated with Waldenström Macroglobulinemia
by: Tanawan Riangwiwat, et al.
Published: (2016-01-01) -
Focal Segmental Glomerulosclerosis in Waldenström’s Macroglobulinemia
by: Akshee Batra, et al.
Published: (2020-01-01) -
Systemic Amyloidosis and Cardiac Autonomic Neuropathy Associated with Waldenstrom’s Macroglobulinemia
by: Aasems Jacob, et al.
Published: (2017-01-01) -
Waldenström Macroglobulinemia and Cerebral Venous Thrombosis: From Diagnosis to Complication
by: Paulo Zoé Costa, et al.
Published: (2019-01-01)